<DOC>
	<DOCNO>NCT00037622</DOCNO>
	<brief_summary>The purpose study determine safety antiviral HBV activity ACH-126,443 ( beta-L-Fd4C ) treatment Subjects Previous Achillion-Sponsored Phase 1 2 Studies Chronic Hepatitis B Infection .</brief_summary>
	<brief_title>Safety Antiviral Study ACH-126 , 443 ( Beta-L-Fd4C ) Treatment Adults With Chronic Hepatitis B Infection .</brief_title>
	<detailed_description>Evaluation safety antiviral activity 5mg dose ACH-126,443 three month treatment population describe .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Participants previous Phase 1 2 trial ACH126,443 meet entry criterion previous study . Adults ? 18 year age Chronic HBV infection , know HbsAg positive ? 6 month Plasma HBV DNA level ? 100,000 copies/mL prior initiation ACH126,443 earlier study Plasma HBV DNA level medical judgment investigator , warrant 's antiviral treatment HIV negative Basic hematologic chemistry parameter within acceptable limit ( define protocol ) No need exclude medication Subjects reproductive capability must either practice abstinence utilize two approve form birth control , one must barrier protection ( condom spermicidal , diaphragm spermicidal ) Exclusion Criteria HIV infection Active Hepatitis C coinfection Concurrent systemic antiviral treatment Treatment HBV infection lamivudine ( 3TC ) long three ( 3 ) month since participation previous trial ACH126,443 Previous therapy agent significant systemic myelosuppressive cytotoxic potential within 3 month study start expect need therapy study start Alcohol abuse Pregnancy breastfeed Inability tolerate oral medication AST &gt; 10.0 time upper limit normal ALT &gt; 10.0 time upper limit normal Any clinical condition prior therapy , Investigators opinion , would make subject unsuitable study unable comply dose requirement Use investigational drug approve Medical Monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>E-antigen positive , treatment na√Øve chronic HBV infect , lamivudine resistant chronic Hepatitis B , Achillion</keyword>
</DOC>